CLINICAL TRIALS PROFILE FOR BELVIQ
✉ Email this page to a colleague
All Clinical Trials for Belviq
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01880502 ↗ | Pharmacokinetic Study of Belviq in Adult Korean Volunteers | Completed | IlDong Pharmaceutical Co Ltd | Phase 1 | 2013-06-01 | A randomized, double-blind, placebo-controlled, single-dose, dose escalation study (Phase I) to evaluate the tolerability and pharmacokinetics of Belviq in adult Korean volunteers. |
| NCT01962402 ↗ | Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study | Unknown status | Southern California Institute for Research and Education | Phase 4 | 2014-01-01 | The purpose of this study is to determine whether lorcaserin is effective for weight reduction in patients with weight gain as a result of antipsychotic medications. |
| NCT02019264 ↗ | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul | Completed | Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization | Phase 4 | 2014-01-24 | This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors. |
| NCT02019264 ↗ | A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Mul | Completed | Eisai Inc. | Phase 4 | 2014-01-24 | This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors. |
| NCT02022956 ↗ | Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age | Completed | Arena Pharmaceuticals | Phase 1 | 2013-12-01 | The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old |
| NCT02022956 ↗ | Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age | Completed | Eisai Inc. | Phase 1 | 2013-12-01 | The purpose of this study is to evaluate the PK properties, tolerability, and safety of lorcaserin HCL (BELVIQ) in obese adolescent subjects between the ages of 12 to 17 years old |
| NCT02044874 ↗ | A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation | Completed | Arena Pharmaceuticals | Phase 2 | 2014-03-01 | In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Belviq
Condition Name
Clinical Trial Locations for Belviq
Trials by Country
Clinical Trial Progress for Belviq
Clinical Trial Phase
Clinical Trial Sponsors for Belviq
Sponsor Name
